Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.

What Was Tested

This randomized controlled trial looks at Amlodipine and Ramipril.

The aldosterone-to-renin ratio (ARR) is frequently used to screen primary hyperaldosteronism.

This study, part of a clinical trial, was designed to measure the influence of circadian rhythms, antihypertensive drugs, and body posture on plasma renin, on aldosterone, and on their interrelation.

Who Took Part

The study group was 41 men.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

The men were allocated by chance, so the Amlodipine group and the comparison group should start out alike.

Everyone knew when Amlodipine was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The Amlodipine group and the comparison group ran side by side rather than switching.

What Was Measured

The aldosterone-to-renin ratio (ARR) is frequently used to screen primary hyperaldosteronism.

This study, part of a clinical trial, was designed to measure the influence of circadian rhythms, antihypertensive drugs, and body posture on plasma renin, on aldosterone, and on their interrelation.

The subject headings attached to it are Aldosterone, Amlodipine, Angiotensin II Type 1 Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzimidazoles and Benzoates.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Amlodipine and Ramipril in 41 men.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2005 (American journal of hypertension), a journal based in United States.

More context: all human trials.